Revision: March 12, 2024, 1:58 p.m.
Rep. Hoell, Merr. 27
March 5, 2024
2024-0972h
09/05
Amendment to HB 1664-FN
Amend RSA 507-E:1, II-a as inserted by section 1 of the bill by replacing it with the following:
II-a. “Medical detransition” means treatment received by an individual for the purpose of reversing or mitigating the effects of gender transition surgery, cross-sex hormones, or puberty-blocking drugs and of restoring the secondary sex characteristics corresponding to the individual’s sex as defined in RSA 354-A:2, XIV-f.
Amend the bill by replacing section 2 with the following:
2 New Section; Actions, Process, and Service of Process; Medical Injury Actions; Actions for Medical Detransitioning. Amend RSA 507-E by inserting after section 4 the following new section:
507-E:5 Actions for Medical Detransition.
I. Any action for a medical injury resulting from the administration or prescription of gender transition surgery, cross-sex hormones, or puberty-blocking drugs shall accrue under RSA 508:4, I no earlier than the time the plaintiff begins a medical detransition.
II. A plaintiff who brings any action listed in paragraph I shall be presumed to have met the plaintiff’s burden under RSA 507-E:2, I if the individual is infertile as a result of the treatment. Such presumption may be rebutted only by clear and convincing evidence.